PDCD1 and metastatic melanoma: In our analysis, the parameters SUVmax and k3 derived from interim PET/CT positively affected the patient suggesting that the degree of activation of the bone marrow during PD-1 blockade, as reflected by respective changes in 18F-FDG uptake and kinetics, may play a predictive role in treatment outcome of metastatic melanoma.